PPARs as therapeutic targets in cardiovascular disease

Area of Science:

• Cardiovascular research
• Molecular endocrinology
• Metabolic disease

Background:

• Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors crucial for lipid and glucose metabolism.
• PPARs have been targeted for treating metabolic diseases like hyperlipidemia and type-2 diabetes.
• Their lipid-lowering effects indirectly reduce cardiovascular disease risk, particularly atherosclerosis.

Purpose of the Study:

• To review the pleiotropic effects of PPAR isotypes (PPARα, PPARδ, PPARγ) on vascular and cardiac disease.
• To emphasize the molecular mechanisms and preclinical findings related to PPARs in cardiovascular contexts.
• To explore the potential therapeutic applications and challenges of PPAR-targeting strategies.

Main Methods:

• Discussion of preclinical studies on PPAR ligands and their impact on cardiovascular conditions.
• Analysis of the molecular mechanisms underlying PPAR actions, including effects on inflammation and cell fate.
• Review of existing literature on PPARs in the context of atherosclerosis, ischemic heart disease, and cardiac failure.

Main Results:

• Preclinical data suggest PPAR ligands affect atherogenesis, ischemic heart disease, and cardiac failure development.
• PPARs modulate vital processes beyond metabolism, including inflammation and cell fate (proliferation, differentiation, apoptosis).
• The clinical translatability of these preclinical observations requires further investigation.

Conclusions:

• The diverse mechanisms of PPARs offer broad therapeutic potential for cardiovascular diseases.
• The versatility of PPARs presents challenges in achieving specific therapeutic effects without adverse side effects.
• Future research should focus on developing PPAR-based strategies that mitigate detrimental side effects for safer clinical application.